Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 165

1.

Low lean mass and chemotherapy toxicity risk in the elderly: the Fraction study protocol.

Steinmeyer Z, Gérard S, Filleron T, Lozano S, Brechemier D, Abellan Van Kan G, Mourey L, Cristol-Dalstein L, De Decker L, Rolland Y, Balardy L.

BMC Cancer. 2019 Nov 27;19(1):1153. doi: 10.1186/s12885-019-6377-7.

2.

Anti-TNF, a magic bullet in cancer immunotherapy?

Montfort A, Dufau C, Colacios C, Andrieu-Abadie N, Levade T, Filleron T, Delord JP, Ayyoub M, Meyer N, Ségui B.

J Immunother Cancer. 2019 Nov 14;7(1):303. doi: 10.1186/s40425-019-0802-y.

3.

Prognostic role of CD4 T-cell depletion after frontline fludarabine, cyclophosphamide and rituximab in chronic lymphocytic leukaemia.

Gauthier M, Durrieu F, Martin E, Peres M, Vergez F, Filleron T, Obéric L, Bijou F, Quillet Mary A, Ysebaert L.

BMC Cancer. 2019 Aug 14;19(1):809. doi: 10.1186/s12885-019-5971-z.

4.

Cutaneous Squamous Cell Carcinoma Tumour Size is Associated with Sentinel Lymph Node Metastasis in a Cohort of 69 Patients.

Chabrillac E, Lusque A, Cavallier Z, Lopez R, Filleron T, Sarini J, Meyer N, Vergez S.

Acta Derm Venereol. 2019 Aug 13. doi: 10.2340/00015555-3293. [Epub ahead of print]

5.

Goftte: A R package for assessing goodness-of-fit in proportional (sub) distributions hazards regression models.

Sfumato P, Filleron T, Giorgi R, Cook RJ, Boher JM.

Comput Methods Programs Biomed. 2019 Aug;177:269-275. doi: 10.1016/j.cmpb.2019.05.029. Epub 2019 May 30.

PMID:
31319955
6.

Author Correction: Genomic characterization of metastatic breast cancers.

Bertucci F, Ng CKY, Patsouris A, Droin N, Piscuoglio S, Carbuccia N, Soria JC, Dien AT, Adnani Y, Kamal M, Garnier S, Meurice G, Jimenez M, Dogan S, Verret B, Chaffanet M, Bachelot T, Campone M, Lefeuvre C, Bonnefoi H, Dalenc F, Jacquet A, De Filippo MR, Babbar N, Birnbaum D, Filleron T, Le Tourneau C, André F.

Nature. 2019 Aug;572(7767):E7. doi: 10.1038/s41586-019-1380-3.

PMID:
31308536
7.

PIK3CA mutations early persistence in cell-free tumor DNA as a negative prognostic factor in metastatic breast cancer patients treated with hormonal therapy.

Jacot W, Dalenc F, Lopez-Crapez E, Chaltiel L, Durigova A, Gros N, Lozano N, Lacaze JL, Pouderoux S, Gladieff L, Romieu G, Roché H, Filleron T, Lamy PJ.

Breast Cancer Res Treat. 2019 Oct;177(3):659-667. doi: 10.1007/s10549-019-05349-y. Epub 2019 Jul 11.

PMID:
31297647
8.

[Management of non-small cell lung cancer patients harboring activating mutations and CNS progression].

Rouviere D, Veillon R, Chaltiel L, Simonneau Y, Filleron T, Milia J, Guibert N, Melloni B, Raherison C, Didier A, Mazieres J.

Rev Mal Respir. 2019 May;36(5):583-590. doi: 10.1016/j.rmr.2019.04.003. Epub 2019 Jun 13. French.

PMID:
31202602
9.

Genomic characterization of metastatic breast cancers.

Bertucci F, Ng CKY, Patsouris A, Droin N, Piscuoglio S, Carbuccia N, Soria JC, Dien AT, Adnani Y, Kamal M, Garnier S, Meurice G, Jimenez M, Dogan S, Verret B, Chaffanet M, Bachelot T, Campone M, Lefeuvre C, Bonnefoi H, Dalenc F, Jacquet A, De Filippo MR, Babbar N, Birnbaum D, Filleron T, Le Tourneau C, André F.

Nature. 2019 May;569(7757):560-564. doi: 10.1038/s41586-019-1056-z. Epub 2019 May 22. Erratum in: Nature. 2019 Aug;572(7767):E7.

PMID:
31118521
10.

Sphingomyelin Synthase 1 (SMS1) Downregulation Is Associated With Sphingolipid Reprogramming and a Worse Prognosis in Melanoma.

Bilal F, Montfort A, Gilhodes J, Garcia V, Riond J, Carpentier S, Filleron T, Colacios C, Levade T, Daher A, Meyer N, Andrieu-Abadie N, Ségui B.

Front Pharmacol. 2019 Apr 30;10:443. doi: 10.3389/fphar.2019.00443. eCollection 2019.

11.

Gated 18F-FDG PET/CT of the Lung Using a Respiratory Spirometric Gating Device: A Feasibility Study.

Jaudet C, Filleron T, Weyts K, Didierlaurent D, Vallot D, Ouali M, Zerdoud S, Dierickx OL, Caselles O, Courbon F.

J Nucl Med Technol. 2019 Sep;47(3):227-232. doi: 10.2967/jnmt.118.223339. Epub 2019 Apr 24.

PMID:
31019044
12.

Éditorial.

Andrieu S, Filleron T; Comités scientifique et d’organisation.

Rev Epidemiol Sante Publique. 2019 May;67 Suppl 3:S119. doi: 10.1016/j.respe.2019.03.001. Epub 2019 Apr 5. French. No abstract available.

PMID:
30955996
13.

The GIRAFE phase II trial on MVCT-based "volumes of the day" and "dose of the day" addresses when and how to implement adaptive radiotherapy for locally advanced head and neck cancer.

Esteyrie V, Gleyzolle B, Lusque A, Graff P, Modesto A, Rives M, Lapeyre M, Desrousseaux J, Graulières E, Hangard G, Arnaud FX, Ferrand R, Delord JP, Poublanc M, Mounier M, Filleron T, Laprie A.

Clin Transl Radiat Oncol. 2019 Mar 9;16:34-39. doi: 10.1016/j.ctro.2019.02.006. eCollection 2019 May.

14.

Dose-painting multicenter phase III trial in newly diagnosed glioblastoma: the SPECTRO-GLIO trial comparing arm A standard radiochemotherapy to arm B radiochemotherapy with simultaneous integrated boost guided by MR spectroscopic imaging.

Laprie A, Ken S, Filleron T, Lubrano V, Vieillevigne L, Tensaouti F, Catalaa I, Boetto S, Khalifa J, Attal J, Peyraga G, Gomez-Roca C, Uro-Coste E, Noel G, Truc G, Sunyach MP, Magné N, Charissoux M, Supiot S, Bernier V, Mounier M, Poublanc M, Fabre A, Delord JP, Cohen-Jonathan Moyal E.

BMC Cancer. 2019 Feb 21;19(1):167. doi: 10.1186/s12885-019-5317-x.

15.

Factors Affecting Tamoxifen Metabolism in Patients With Breast Cancer: Preliminary Results of the French PHACS Study.

Puszkiel A, Arellano C, Vachoux C, Evrard A, Le Morvan V, Boyer JC, Robert J, Delmas C, Dalenc F, Debled M, Venat-Bouvet L, Jacot W, Suc E, Sillet-Bach I, Filleron T, Roché H, Chatelut E, White-Koning M, Thomas F.

Clin Pharmacol Ther. 2019 Sep;106(3):585-595. doi: 10.1002/cpt.1404. Epub 2019 Apr 10.

PMID:
30786012
16.

Survival Impact of Locoregional Treatment of the Primary Tumor in De Novo Metastatic Breast Cancers in a Large Multicentric Cohort Study: A Propensity Score-Matched Analysis.

Pons-Tostivint E, Kirova Y, Lusque A, Campone M, Geffrelot J, Mazouni C, Mailliez A, Pasquier D, Madranges N, Firmin N, Crouzet A, Gonçalves A, Jankowski C, De La Motte Rouge T, Pouget N, de La Lande B, Mouttet-Boizat D, Ferrero JM, Uwer L, Eymard JC, Mouret-Reynier MA, Petit T, Robain M, Filleron T, Cailliot C, Dalenc F.

Ann Surg Oncol. 2019 Feb;26(2):356-365. doi: 10.1245/s10434-018-6831-9. Epub 2018 Dec 11.

PMID:
30539492
17.

Targeting the Sphingosine 1-Phosphate Axis Exerts Potent Antitumor Activity in BRAFi-Resistant Melanomas.

Garandeau D, Noujarède J, Leclerc J, Imbert C, Garcia V, Bats ML, Rambow F, Gilhodes J, Filleron T, Meyer N, Brayer S, Arcucci S, Tartare-Deckert S, Ségui B, Marine JC, Levade T, Bertolotto C, Andrieu-Abadie N.

Mol Cancer Ther. 2019 Feb;18(2):289-300. doi: 10.1158/1535-7163.MCT-17-1141. Epub 2018 Nov 27.

PMID:
30482853
18.

Experimental study of pelvic perioperative brachytherapy with iodine 125 seeds (I-125) in an animal model.

Brun T, Ferron G, Filleron T, Bonnet J, Martinez A, Ducassou A, Corbiere F, Delannes M.

J Contemp Brachytherapy. 2018 Oct;10(5):463-469. doi: 10.5114/jcb.2018.79470. Epub 2018 Oct 31.

19.

Prospective evaluation of the performances of narrow-band imaging flexible videoscopy relative to white-light imaging flexible videoscopy, in patients scheduled for transurethral resection of a primary NMIBC.

Dalgaard LP, Zare R, Gaya JM, Redorta JP, Roumiguié M, Filleron T, Malavaud B.

World J Urol. 2019 Aug;37(8):1615-1621. doi: 10.1007/s00345-018-2537-7. Epub 2018 Oct 26.

PMID:
30367204
20.

Estimation of Unbound Carboplatin Clearance From Total Plasma Concentrations as a Means of Facilitating Therapeutic Drug Monitoring.

Moeung S, Chevreau C, Poinsignon V, Guitton J, Lelièvre B, Ciccolini J, Gladieff L, Massart C, Fléchon A, Delva R, Gravis G, Lotz JP, Bay JO, Gross-Goupil M, Delahousse J, Filleron T, Lochon I, Chatelut E, Thomas F.

Ther Drug Monit. 2019 Feb;41(1):66-74. doi: 10.1097/FTD.0000000000000569.

PMID:
30299429
21.

Inhibiting Integrin β8 to Differentiate and Radiosensitize Glioblastoma-Initiating Cells.

Malric L, Monferran S, Delmas C, Arnauduc F, Dahan P, Boyrie S, Deshors P, Lubrano V, Da Mota DF, Gilhodes J, Filleron T, Siegfried A, Evrard S, Kowalski-Chauvel A, Moyal EC, Toulas C, Lemarié A.

Mol Cancer Res. 2019 Feb;17(2):384-397. doi: 10.1158/1541-7786.MCR-18-0386. Epub 2018 Sep 28.

PMID:
30266751
22.

Addressing heterogeneity in the design of phase II clinical trials in geriatric oncology.

Cabarrou B, Sfumato P, Mourey L, Leconte E, Balardy L, Martinez A, Delord JP, Boher JM, Brain E, Filleron T.

Eur J Cancer. 2018 Nov;103:120-126. doi: 10.1016/j.ejca.2018.07.136. Epub 2018 Sep 14.

PMID:
30223225
23.

Evaluation of eight melanocytic and neural crest-associated markers in a well-characterised series of 124 malignant peripheral nerve sheath tumours (MPNST): useful to distinguish MPNST from melanoma?

Gaspard M, Lamant L, Tournier E, Valentin T, Rochaix P, Terrier P, Ranchere-Vince D, Coindre JM, Filleron T, Le Guellec S.

Histopathology. 2018 Dec;73(6):969-982. doi: 10.1111/his.13740. Epub 2018 Oct 23.

PMID:
30137667
24.

Focus on an infrequently used quantity in the context of competing risks: The conditional probability function.

Cabarrou B, Dalenc F, Leconte E, Boher JM, Filleron T.

Comput Biol Med. 2018 Oct 1;101:70-81. doi: 10.1016/j.compbiomed.2018.08.002. Epub 2018 Aug 4.

PMID:
30103091
25.

Designing phase II clinical trials to target subgroup of interest in a heterogeneous population: A case study using an R package.

Cabarrou B, Sfumato P, Leconte E, Boher JM, Filleron T.

Comput Biol Med. 2018 Sep 1;100:239-246. doi: 10.1016/j.compbiomed.2018.06.034. Epub 2018 Jun 30.

PMID:
30055524
26.

Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients With RET-Rearranged Lung Cancers.

Drilon A, Lin JJ, Filleron T, Ni A, Milia J, Bergagnini I, Hatzoglou V, Velcheti V, Offin M, Li B, Carbone DP, Besse B, Mok T, Awad MM, Wolf J, Owen D, Camidge DR, Riely GJ, Peled N, Kris MG, Mazieres J, Gainor JF, Gautschi O.

J Thorac Oncol. 2018 Oct;13(10):1595-1601. doi: 10.1016/j.jtho.2018.07.004. Epub 2018 Jul 11.

27.

Clinical, histological and molecular predictors of metastatic melanoma responses to anti-PD-1 immunotherapy.

Dupuis F, Lamant L, Gerard E, Torossian N, Chaltiel L, Filleron T, Beylot-Barry M, Dutriaux C, Prey S, Gros A, Jullie ML, Meyer N, Vergier B.

Br J Cancer. 2018 Jul;119(2):193-199. doi: 10.1038/s41416-018-0168-9. Epub 2018 Jul 5.

28.

Efficacy of chemotherapy or chemo-anti-PD-1 combination after failed anti-PD-1 therapy for relapsed and refractory Hodgkin lymphoma: A series from Lysa centers.

Rossi C, Gilhodes J, Maerevoet M, Herbaux C, Morschhauser F, Brice P, Garciaz S, Borel C, Ysebaert L, Obéric L, Lazarovici J, Deau B, Dupuis J, Chauchet A, Abraham J, Bijou F, Stamatoullas-Bastard A, Malfuson JV, Golfier C, Laurent C, Pericart S, Traverse-Glehen A, Kanoun S, Filleron T, Casasnovas RO, Ghesquières H.

Am J Hematol. 2018 Jun 8. doi: 10.1002/ajh.25154. [Epub ahead of print]

29.

Validation of the Complexity INdex in SARComas prognostic signature on formalin-fixed, paraffin-embedded, soft-tissue sarcomas.

Le Guellec S, Lesluyes T, Sarot E, Valle C, Filleron T, Rochaix P, Valentin T, Pérot G, Coindre JM, Chibon F.

Ann Oncol. 2018 Aug 1;29(8):1828-1835. doi: 10.1093/annonc/mdy194.

PMID:
29860427
30.

The 21-gene Recurrence Score® assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 trial).

Penault-Llorca F, Filleron T, Asselain B, Baehner FL, Fumoleau P, Lacroix-Triki M, Anderson JM, Yoshizawa C, Cherbavaz DB, Shak S, Roca L, Sagan C, Lemonnier J, Martin AL, Roché H.

BMC Cancer. 2018 May 4;18(1):526. doi: 10.1186/s12885-018-4331-8.

31.

The importance of jointly analyzing treatment administration and toxicity associated with targeted therapies: a case study of regorafenib in soft tissue sarcoma patients.

Longué M, Cabarrou B, Wallet J, Brodowicz T, Roché H, Boher JM, Delord JP, Penel N, Filleron T.

Ann Oncol. 2018 Jul 1;29(7):1588-1593. doi: 10.1093/annonc/mdy168.

PMID:
29722789
32.

Alternative methodological approach to randomized trial for surgical procedures routinely used.

Filleron T, Lusque A, Dalenc F, Ferron G, Roche H, Martinez A, Jouve E.

Contemp Clin Trials. 2018 May;68:109-115. doi: 10.1016/j.cct.2018.03.016. Epub 2018 Mar 30.

PMID:
29608972
33.

DNA polymerase ν gene expression influences fludarabine resistance in chronic lymphocytic leukemia independently of p53 status.

Grgurevic S, Montilla-Perez P, Bradbury A, Gilhodes J, Queille S, Pelofy S, Bancaud A, Filleron T, Ysebaert L, Récher C, Laurent G, Fournié JJ, Cazaux C, Quillet-Mary A, Hoffmann JS.

Haematologica. 2018 Jun;103(6):1038-1046. doi: 10.3324/haematol.2017.174243. Epub 2018 Mar 22.

34.

New approach of ultra-focal brachytherapy for low- and intermediate-risk prostate cancer with custom-linked I-125 seeds: A feasibility study of optimal dose coverage.

Brun T, Bachaud JM, Graff-Cailleaud P, Malavaud B, Portalez D, Popotte C, Aziza R, Lusque A, Filleron T, Ken S.

Brachytherapy. 2018 May - Jun;17(3):544-555. doi: 10.1016/j.brachy.2018.01.011. Epub 2018 Mar 7.

PMID:
29525514
35.

IDEAL 2a Phase II Study of Ultrafocal Brachytherapy for Low- and Intermediate-risk Prostate Cancer.

Graff P, Portalez D, Lusque A, Brun T, Aziza R, Khalifa J, Roumiguié M, Quintyn Ranty ML, Filleron T, Bachaud JM, Malavaud B.

Int J Radiat Oncol Biol Phys. 2018 Nov 15;102(4):903-911. doi: 10.1016/j.ijrobp.2018.01.066. Epub 2018 Feb 2.

PMID:
29510957
36.

Total body irradiation using Helical Tomotherapy®: Treatment technique, dosimetric results and initial clinical experience.

Sarradin V, Simon L, Huynh A, Gilhodes J, Filleron T, Izar F.

Cancer Radiother. 2018 Feb;22(1):17-24. doi: 10.1016/j.canrad.2017.06.014.

PMID:
29395854
37.

Comparing sensitivity and specificity of medical imaging tests when verification bias is present: The concept of relative diagnostic accuracy.

Filleron T.

Eur J Radiol. 2018 Jan;98:32-35. doi: 10.1016/j.ejrad.2017.10.022. Epub 2017 Oct 31. Review.

PMID:
29279167
38.

TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma.

Bertrand F, Montfort A, Marcheteau E, Imbert C, Gilhodes J, Filleron T, Rochaix P, Andrieu-Abadie N, Levade T, Meyer N, Colacios C, Ségui B.

Nat Commun. 2017 Dec 22;8(1):2256. doi: 10.1038/s41467-017-02358-7.

39.

Continuous Infusion of Cilengitide Plus Chemoradiotherapy for Patients With Stage III Non-Small-cell Lung Cancer: A Phase I Study.

Massabeau C, Khalifa J, Filleron T, Modesto A, Bigay-Gamé L, Plat G, Dierickx L, Aziza R, Rouquette I, Gomez-Roca C, Mounier M, Delord JP, Toulas C, Olivier P, Chatelut E, Mazières J, Cohen-Jonathan Moyal E.

Clin Lung Cancer. 2018 May;19(3):e277-e285. doi: 10.1016/j.cllc.2017.11.002. Epub 2017 Nov 21.

PMID:
29221762
40.

[Nomograms in routine clinical practice: Methodology, interest and limitations].

Filleron T, Chaltiel L, Jouve E, Cabarrou B, Gilhodes J, Lusque A, Mery E, Dalenc F, Martinez A.

Bull Cancer. 2018 Jan;105(1):15-24. doi: 10.1016/j.bulcan.2017.10.024. Epub 2017 Dec 6. French.

PMID:
29221620
41.

Prospective Assessment of First-Year Quality of Life After Pelvic Exenteration for Gynecologic Malignancy: A French Multicentric Study.

Martinez A, Filleron T, Rouanet P, Méeus P, Lambaudie E, Classe JM, Foucher F, Narducci F, Gouy S, Guyon F, Marchal F, Jouve E, Colombo PE, Mourregot A, Rivoire M, Chopin N, Houvenaeghel G, Jaffre I, Leveque J, Lavoue V, Leblanc E, Morice P, Stoeckle E, Verheaghe JL, Querleu D, Ferron G.

Ann Surg Oncol. 2018 Feb;25(2):535-541. doi: 10.1245/s10434-017-6120-z. Epub 2017 Nov 20.

PMID:
29159738
42.

Interest of integrins targeting in glioblastoma according to tumor heterogeneity and cancer stem cell paradigm: an update.

Malric L, Monferran S, Gilhodes J, Boyrie S, Dahan P, Skuli N, Sesen J, Filleron T, Kowalski-Chauvel A, Cohen-Jonathan Moyal E, Toulas C, Lemarié A.

Oncotarget. 2017 Aug 21;8(49):86947-86968. doi: 10.18632/oncotarget.20372. eCollection 2017 Oct 17. Review.

43.

Identification of a tumor-promoter cholesterol metabolite in human breast cancers acting through the glucocorticoid receptor.

Voisin M, de Medina P, Mallinger A, Dalenc F, Huc-Claustre E, Leignadier J, Serhan N, Soules R, Ségala G, Mougel A, Noguer E, Mhamdi L, Bacquié E, Iuliano L, Zerbinati C, Lacroix-Triki M, Chaltiel L, Filleron T, Cavaillès V, Al Saati T, Rochaix P, Duprez-Paumier R, Franchet C, Ligat L, Lopez F, Record M, Poirot M, Silvente-Poirot S.

Proc Natl Acad Sci U S A. 2017 Oct 31;114(44):E9346-E9355. doi: 10.1073/pnas.1707965114. Epub 2017 Oct 12.

44.

Comparison of variable selection methods for high-dimensional survival data with competing events.

Gilhodes J, Zemmour C, Ajana S, Martinez A, Delord JP, Leconte E, Boher JM, Filleron T.

Comput Biol Med. 2017 Dec 1;91:159-167. doi: 10.1016/j.compbiomed.2017.10.021. Epub 2017 Oct 20.

PMID:
29078093
45.

CD163-positive tumor-associated macrophages and CD8-positive cytotoxic lymphocytes are powerful diagnostic markers for the therapeutic stratification of osteosarcoma patients: An immunohistochemical analysis of the biopsies fromthe French OS2006 phase 3 trial.

Gomez-Brouchet A, Illac C, Gilhodes J, Bouvier C, Aubert S, Guinebretiere JM, Marie B, Larousserie F, Entz-Werlé N, de Pinieux G, Filleron T, Minard V, Minville V, Mascard E, Gouin F, Jimenez M, Ledeley MC, Piperno-Neumann S, Brugieres L, Rédini F.

Oncoimmunology. 2017 Aug 24;6(9):e1331193. doi: 10.1080/2162402X.2017.1331193. eCollection 2017.

46.

Loss of H3K27 trimethylation is not suitable for distinguishing malignant peripheral nerve sheath tumor from melanoma: a study of 387 cases including mimicking lesions.

Le Guellec S, Macagno N, Velasco V, Lamant L, Lae M, Filleron T, Malissen N, Cassagnau E, Terrier P, Chevreau C, Ranchere-Vince D, Coindre JM.

Mod Pathol. 2017 Dec;30(12):1677-1687. doi: 10.1038/modpathol.2017.91. Epub 2017 Jul 28.

47.

Cell-assisted lipotransfer: Friend or foe in fat grafting? Systematic review and meta-analysis.

Laloze J, Varin A, Gilhodes J, Bertheuil N, Grolleau JL, Brie J, Usseglio J, Sensebe L, Filleron T, Chaput B.

J Tissue Eng Regen Med. 2018 Feb;12(2):e1237-e1250. doi: 10.1002/term.2524. Epub 2017 Dec 7.

PMID:
28719946
48.

Impact of surgery on survival in stage IV breast cancer.

Filleron T, Pons E, Lusque A, Dalenc F.

Breast J. 2017 Nov;23(6):774. doi: 10.1111/tbj.12822. Epub 2017 May 15. No abstract available.

PMID:
28503823
49.

Methodology of phase II clinical trials in metastatic elderly breast cancer: a literature review.

Cabarrou B, Mourey L, Dalenc F, Balardy L, Kanoun D, Roché H, Boher JM, Rougé-Bugat ME, Filleron T.

Breast Cancer Res Treat. 2017 Aug;164(3):505-513. doi: 10.1007/s10549-017-4278-5. Epub 2017 May 9. Review.

PMID:
28488143
50.

Impact of Expert Pathologic Review of Lymphoma Diagnosis: Study of Patients From the French Lymphopath Network.

Laurent C, Baron M, Amara N, Haioun C, Dandoit M, Maynadié M, Parrens M, Vergier B, Copie-Bergman C, Fabiani B, Traverse-Glehen A, Brousse N, Copin MC, Tas P, Petrella T, Rousselet MC, Brière J, Charlotte F, Chassagne-Clement C, Rousset T, Xerri L, Moreau A, Martin A, Damotte D, Dartigues P, Soubeyran I, Peoch M, Dechelotte P, Michiels JF, de Mascarel A, Berger F, Bossard C, Arbion F, Quintin-Roué I, Picquenot JM, Patey M, Fabre B, Sevestre H, Le Naoures C, Chenard-Neu MP, Bastien C, Thiebault S, Martin L, Delage M, Filleron T, Salles G, Molina TJ, Delsol G, Brousset P, Gaulard P.

J Clin Oncol. 2017 Jun 20;35(18):2008-2017. doi: 10.1200/JCO.2016.71.2083. Epub 2017 May 1.

PMID:
28459613

Supplemental Content

Loading ...
Support Center